Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole

British Journal of Clinical Pharmacology

Volumn 45, Issue 4, 1998, Pages 369-375

  Andersson, Tommy ^a   Holmberg, Johan ^a   Röhss, Kerstin ^a   Walan, Anders ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Lansoprazole; Omeprazole; Pantoprazole; Pharmacokinetics

Indexed keywords

ANTIULCER AGENT; CAFFEINE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREATH ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG METABOLISM; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ULCER; URINARY EXCRETION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; AREA UNDER CURVE; BENZIMIDAZOLES; BREATH TESTS; CAFFEINE; HUMANS; MALE; OMEPRAZOLE; PROTON PUMPS; SULFOXIDES;

EID: 0031910445     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00702.x     Document Type: Article

References (35)

1. Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Phamacol Ther 1990; 47: 79-85.
2. Kupfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation ploymorphism in man. Eur J Clin Pharmacol 1984; 26: 753-759.
3. Nelson DR, Kamataki T, Waxman DJ, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993; 12: 1-51.
4. Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994; 33: 1743-1752.
5. Andersson T, Regårdh CG, Dahl-Puustinen ML, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990; 12: 415-416.
6. Andersson T, Miners JO, Veronese ME, et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36: 521-530.
7. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T, Ishizaki T. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther 1993; 266; 52-59.
8. 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1992; 52: 170-180.
9. Rost KL, Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: Coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994; 55: 402-411.
10. Andersson T, Bergstrand R, Cederberg C, Eriksson S, Lagerström PO, Skänberg I. Omeprazole treatment does not affect the metabolism of caffeine. Gastroenterology 1991; 101: 943-947.
11. Rizzo N, Padoin C, Palombo S, Scherrmann JM, Girre C. Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapeutic conditions. Eur J Clin Pharmacol 1996; 49: 491-495.
12. Xiaodong S, Gatti G, Bartoli A, Cipolla G, Crema F, Perucca E. Omeprazole does not enhance the metabolism of phenacetin, a marker of CYP1A2 activity, in healthy volunteers. Ther Drug Monit 1994; 16: 248-250.
13. Gugler R, Jensen JC. Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo. Pharmacol Ther 1987; 33: 133-137.
14. Robson RA, Miners JO, Matthews AP, et al. Characterisation of theophylline metabolism by human liver microsomes. Biochem Pharmacol 1988; 37: 1651-1659.
15. Sarkar MA, Hunt C, Guzelian PS, Karnes HT. Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metab Dispos 1992; 20: 31-37.
16. Zhang ZY, Kaminsky LS. Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol 1995; 50: 205-211.
17. Curi-Pedrosa R, Pichard L, Bonfils C, Jacqz-Aigrain E, Maurel P. Major implication of cytochrome P450 3A4 in the oxidative metabolism of the antisecretory drugs omeprazole and lansoprazole in human liver microsomes and hepatocytes. Br J Clin Pharmacol 1993; 36: 156P.
18. Tucker GT. The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther 1994; 8(Suppl 1): 33-38.
19. Pichard L, Curi-Pedrosa R, Bonfils C, et al. Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol 1995; 47: 410-418.
20. Benet LZ, Zech K. Pharmacokinetics - a relevant factor for the choice of a drug? Aliment Pharmacol Ther 1994; 8(Suppl 1): 25-32.
21. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995; 9: 363-378.
22. Schulz H-U, Hartmann M, Steinijans VW, et al. Lack of influence of pantoprazole on the disposition kinetics of theophylline in man. Int J Clin Pharmacol Ther Toxicol 1991; 29: 369-375.
23. Granneman GR, Karol MD, Locke CS, Cavanaugh JH. Pharmacokinctic interaction between lansoprazole and theophylline. Ther Drug Monit 1995; 17: 460-464.
24. Kokufu T, Ihara N, Sugioka N, et al. Effects of lansoprazole on phannacokinetics and metabolism of theophylline. Eur J Clin Pharmacol 1995; 48: 391-395.
25. Sanz EJ, Villén T, Alm C, Bertilsson L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 1989; 45: 495-499.
26. Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987; 42: 157-165.
27. Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther 1983; 33: 591-602.
28. Lagerström PO, Persson BA. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatogr 1984; 309: 347-356.
29. Andersson T. Pharmacokinetics of omeprazole in man; with special reference to single and repeated administration, drug interaction and polymorphic metabolism. Thesis, University of Göteborg, Sweden 1991.
30. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokin 1996; 31: 9-28.
31. Andersson T, Cederberg C, Heggelund A, Lundborg P. The pharmacokinetics of single and repeated once-daily doses of 10, 20 and 40 mg omeprazole as enteric-coated granules. Drug Invest 1991; 3: 45-52.
32. Andersson T, Cederberg C, Lundborg F, Regård CG. Plasma omeprazole concentrations during once daily dosing in slow and rapid metabolisers. In: Ingelman-Sundberg, Gustafsson, Orrenium (eds). Drug metabolising enzymes; genetics, regulation and toxicology. Proceedings of the VIIth International Symposium on microsomes and drug oxidations, Stockholm. Karolinska Institutet, June 25-29, 1990. Abstract no 363.
33. Curi-Pedrosa R, Daujat M, Pichard L, et al. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J Pharmacol Exp Ther 1994; 269: 384-392.
34. Rost KL, Brösicke H, Heinemeyer G, Roots I. Specific and dose-dependent enzyme induction by omeprazole in human beings. Hepatol 1994; 20: 1204-1212.
35. Verdú EF, Fraser R, Armstrong D, Blum AL. Effects of omeprazole and lansoprazole on 24-hour intragastric pH in Helicobacter pylori-positive voolunteers. Scand J Gastroenterol 1994; 29: 1065-1069.